TORONTO, June 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (“Profound” or the “Company”) (TSXV:PRN) is pleased to announce the results of the votes on the matters considered at its Annual Meeting of Shareholders that was held on June 21, 2016. A total of 27,135,424 common shares, representing 68.74% of the shares outstanding, were represented in person and by proxy at the meeting.
1. Election of Directors
At the Meeting, the shareholders of the Company elected all six nominees for the board of directors. Detailed results of the voting in respect of the election of directors are as follows:
|Director||Number of |
|Percentage of Votes|
|Steven Plymale||Votes For:||24,570,323||99.96||%|
|Damian Lamb||Votes For:||24,570,323||99.96||%|
|Jean-François Pariseau||Votes For:||24,570,323||99.96||%|
|William Curran||Votes For:||24,570,323||99.96||%|
|Arun Menawat||Votes For:||24,570,323||99.96||%|
|Jonathan Goodman||Votes For:||24,570,323||99.96||%|
2. Appointment of Auditors
At the Meeting, the shareholders of the Company appointed PricewaterhouseCoopers LLP to serve as the independent auditors for 2016.
|Auditors||Number of |
|Percentage of Votes|
|PricewaterhouseCoopers LLP||Votes For:||27,135,424||100||%|
About Profound Medical Corp.
Profound is a Canadian medical device company that developed a unique and minimally invasive procedure to ablate malignant prostate tissue. The Company’s novel technology combines real-time Magnetic Resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit www.profoundmedical.com
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Media: Rebecca von Goetz Senior Marketing & Communications Specialist Profound Medical Corp. firstname.lastname@example.org T: 647.476.1350 Ext. 426 C: 416.917.8650 Investors: Steve Plymale CEO Profound Medical Corp. email@example.com T: 647.476.1350 Ext. 401 C: 514.882.3258 Or Stephen Kilmer Investor Relations firstname.lastname@example.org T: 647.872.4849